SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis

SOX17 has been implicated in arterial specification and the maintenance of hematopoietic stem cells (HSCs) in the murine embryo. However, knowledge about molecular pathways and stage-specific effects of SOX17 in humans remains limited. Here, using SOX17-knockout and SOX17-inducible human pluripotent...

Full description

Saved in:
Bibliographic Details
Published inCell reports (Cambridge) Vol. 34; no. 7; p. 108758
Main Authors Jung, Ho Sun, Uenishi, Gene, Park, Mi Ae, Liu, Peng, Suknuntha, Kran, Raymond, Matthew, Choi, Yoon Jung, Thomson, James A., Ong, Irene M., Slukvin, Igor I.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 16.02.2021
Subjects
Online AccessGet full text
ISSN2211-1247
2211-1247
DOI10.1016/j.celrep.2021.108758

Cover

More Information
Summary:SOX17 has been implicated in arterial specification and the maintenance of hematopoietic stem cells (HSCs) in the murine embryo. However, knowledge about molecular pathways and stage-specific effects of SOX17 in humans remains limited. Here, using SOX17-knockout and SOX17-inducible human pluripotent stem cells (hPSCs), paired with molecular profiling studies, we reveal that SOX17 is a master regulator of HOXA and arterial programs in hemogenic endothelium (HE) and is required for the specification of HE with robust lympho-myeloid potential and DLL4+CXCR4+ phenotype resembling arterial HE at the sites of HSC emergence. Along with the activation of NOTCH signaling, SOX17 directly activates CDX2 expression, leading to the upregulation of the HOXA cluster genes. Since deficiencies in HOXA and NOTCH signaling contribute to the impaired in vivo engraftment of hPSC-derived hematopoietic cells, the identification of SOX17 as a key regulator linking arterial and HOXA programs in HE may help to program HSC fate from hPSCs. [Display omitted] •SOX17 is required for specification of DLL4+CXCR4+ arterial hemogenic endothelium (HE)•DLL4+CXCR4+ arterial HE possesses robust lympho-myeloid potential•Along with induction of arterial program, SOX17 activates HOXA gene expression in HE•SOX17 effects in HE are mediated through activation of CDX2 and NOTCH signaling Jung et al. report that SOX17 is a critical upstream factor that is required for the activation and linkage of HOXA and arterial programs in the hemogenic endothelium and for establishing DLL4+CXCR4+ arterial hemogenic endothelium with definitive lympho-myeloid potential. These SOX17 effects are mediated through the activation of CDX2 and NOTCH signaling.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
AUTHOR CONTRIBUTIONS
H.S.J. designed, conducted, and analyzed the experiments, interpreted the experimental data, created the figures, and contributed to manuscript writing. G.U. designed and analyzed the experiments, interpreted the experimental data, and contributed to manuscript writing. M.A.P. performed the western blot assay. P.L. and I.M.O. performed the bioinformatics analysis of the RNA-seq, ATAC-seq, and ChIP-seq studies and contributed to manuscript writing. M.R. performed the cell sorting. K.S. and Y.J.C. performed the realtime qPCR experiments. J.A.T. directed the RNA-seq and ChIP-seq studies. I.I.S. developed the concept, led and supervised the studies, analyzed and interpreted the data, and wrote the manuscript.
ISSN:2211-1247
2211-1247
DOI:10.1016/j.celrep.2021.108758